| pubmed-article:14970301 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0019080 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0010762 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0043031 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0009566 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0542559 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C0538927 | lld:lifeskim |
| pubmed-article:14970301 | lifeskim:mentions | umls-concept:C1882417 | lld:lifeskim |
| pubmed-article:14970301 | pubmed:issue | 940 | lld:pubmed |
| pubmed-article:14970301 | pubmed:dateCreated | 2004-2-18 | lld:pubmed |
| pubmed-article:14970301 | pubmed:abstractText | Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity. | lld:pubmed |
| pubmed-article:14970301 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14970301 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14970301 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14970301 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:14970301 | pubmed:issn | 0032-5473 | lld:pubmed |
| pubmed-article:14970301 | pubmed:author | pubmed-author:GuptaSS | lld:pubmed |
| pubmed-article:14970301 | pubmed:author | pubmed-author:DalyA KAK | lld:pubmed |
| pubmed-article:14970301 | pubmed:author | pubmed-author:AtacBB | lld:pubmed |
| pubmed-article:14970301 | pubmed:author | pubmed-author:MalhiHH | lld:pubmed |
| pubmed-article:14970301 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14970301 | pubmed:volume | 80 | lld:pubmed |
| pubmed-article:14970301 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14970301 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14970301 | pubmed:pagination | 107-9 | lld:pubmed |
| pubmed-article:14970301 | pubmed:dateRevised | 2009-10-22 | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:meshHeading | pubmed-meshheading:14970301... | lld:pubmed |
| pubmed-article:14970301 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14970301 | pubmed:articleTitle | Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. | lld:pubmed |
| pubmed-article:14970301 | pubmed:affiliation | Marion Bessin Liver Research Center and Department of Medicine, Albert Einstein College of Medicine, New York, USA. | lld:pubmed |
| pubmed-article:14970301 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14970301 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14970301 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14970301 | lld:pubmed |
